Breath sniffing device may predict cancer drug success
NCT ID NCT04146064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to develop a non-invasive, inexpensive way to select the right treatment for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
breathprint analysis using an electronic nose device
What this could lead to
If successful, this breath test could help doctors quickly and cheaply identify which patients are likely to benefit from immunotherapy, avoiding ineffective treatments.
What could go wrong
This is an early-stage, observational study. The breath test may not prove accurate enough for routine use, and results may not apply to all cancer types or treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada